Advances in the study of biological agents in the treatment of Crohn’s disease
Crohn’s disease (CD) is a chronic, non-specific intestinal inflammatory disease. A large number of clinical trials have shown that biological agents are effective in inducing remission in patients with CD, and mainte-nance treatment can achieve long-term remission. At present, biological agents are...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of New Medicine
2021-12-01
|
| Series: | Yixue xinzhi zazhi |
| Subjects: | |
| Online Access: | https://yxxz.whuznhmedj.com/storage/attach/2112/ny0owt4kQPZ1HaXCp2UAV0bENdsAtmQZ4Np82O9Y.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Crohn’s disease (CD) is a chronic, non-specific intestinal inflammatory disease. A large number of clinical trials have shown that biological agents are effective in inducing remission in patients with CD, and mainte-nance treatment can achieve long-term remission. At present, biological agents are now being widely used in the treatment of CD and have become the main treatment. These include the anti-tumor necrosis factor (TNF)-α monoclo-nal antibodies, anti-integrin antibody, IL-12/23 monoclonal antibody and a Janus kinase (JAK) inhibitor. In this article, we review the progress and selection of biologics in the treatment of CD. |
|---|---|
| ISSN: | 1004-5511 |